Renal Function Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus with Reduced-Exposure Calcineurin Inhibitor versus Mycophenolate with Standard-Exposure Calcineurin Inhibitor: Results from the TRANSFORM Study

被引：1
|
作者：
Oppenheimer, Federico [1 ]
Russ, Graeme [2 ]
Viklicky, Ondrej [3 ]
Oberbauer, Rainer [4 ]
Garcia, Valter [5 ]
Witzke, Oliver [6 ]
Kuypers, Dirk [7 ]
Danguilan, Romina [8 ]
Das Gupta, Ayan [9 ]
Bernhardt, Peter [10 ]
Sommerer, Claudia [11 ]
机构：
[1] Hosp Clin Barcelona, Barcelona, Spain
[2] Royal Adelaide Hosp, Adelaide, SA, Australia
[3] IKEM, Prague, Czech Republic
[4] Med Univ Vienna, Vienna, Austria
[5] Santa Casa Misericordia Porto Alegre, Porto Alegre, RS, Brazil
[6] Univ Klinikum Essen, Essen, Germany
[7] Gasthuisberg Univ Hosp, Leuven, Belgium
[8] Natl Kidney & Transplant Inst, Quezon City, Philippines
[9] Novartis Healthcare Pvt Ltd, Hyderabad, India
[10] Novartis Pharma AG, Basel, Switzerland
[11] Univ Klinikum Heidelberg, Heidelberg, Germany
来源：
TRANSPLANTATION | 2018年 / 102卷
关键词：
D O I：
10.1097/01.tp.0000543112.91427.9d
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
591.2
引用
收藏
页码：S363 / S363
页数：1
相关论文
共 50 条
  • [1] Everolimus Plus Reduced-Exposure Calcineurin Inhibitor Versus Mycophenolate Mofetil Plus Standard-Exposure Calcineurin Inhibitor: 2-Year Results in Living Donor Kidney Transplant Recipients
    Watarai, Y.
    Akutsu, N.
    Saito, K.
    Nakagawa, Y.
    Kamisawa, O.
    Kenmochi, T.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [2] THE TRANSFORM STUDY: EFFECT OF EVEROLIMUS WITH REDUCED-EXPOSURE CALCINEURIN INHIBITOR ON 12-MONTH RENAL FUNCTION OUTCOMES IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS
    Oppenheimer, Federico
    Witzke, Oliver
    Viklicky, Ondrej
    Cassuto, Elisabeth
    De Fijter, Johan
    Huynh-Do, Uyen
    Russ, Graeme
    Srinivas, Titte
    Luo, Wen-Lin
    Bernhardt, Peter
    Qazi, Yasir
    TRANSPLANT INTERNATIONAL, 2017, 30 : 162 - 162
  • [3] Everolimus with Reduced-Dose Calcineurin Inhibitor versus Mycophenolate with Standard-Dose Calcineurin Inhibitor in De Novo Kidney Transplant Recipients: Renal Function Results from the TRANSFORM Study.
    Oppenheimer, F.
    Legendre, C.
    Cruzado, J.
    Russ, G.
    Viklicky, O.
    Oberbauer, R.
    Garcia, V.
    Witzke, O.
    Kuypers, D.
    Danguilan, R.
    Bernhardt, P.
    Sommerer, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 258 - 258
  • [4] THE TRANSFORM STUDY: INFECTION OUTCOMES WITH EVEROLIMUS PLUS REDUCED CALCINEURIN INHIBITOR AND MYCOPHENOLATE PLUS STANDARD CALCINEURIN INHIBITOR REGIMENS IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS
    Pernin, V.
    Buchler, M.
    Cruzado, J.
    Garcia, V.
    Kuypers, D.
    Citterio, F.
    Huynh-Do, U.
    Luo, W. L.
    Bernhardt, P.
    Sommerer, C.
    Gharbi, H.
    Vincenti, F.
    TRANSPLANT INTERNATIONAL, 2019, 32 : 23 - 23
  • [5] The TRANSFORM Study: Infection Outcomes with Everolimus Plus Reduced Calcineurin Inhibitor and Mycophenolate Plus Standard Calcineurin Inhibitor Regimens in De Novo Kidney Transplant Recipients.
    Vincenti, F.
    Cruzado, J.
    Mulgaonkar, S.
    Garcia, V.
    Kuypers, D.
    Buchler, M.
    Citterio, F.
    Huynh-Do, U.
    Luo, W-L.
    Bernhardt, P.
    Sommerer, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 258 - 258
  • [6] EVEROLIMUS WITH REDUCED CALCINEURIN INHIBITOR EXPOSURE IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS: EFFICACY, SAFETY AND RENAL FUNCTION OUTCOME FROM THE TRANSFORM STUDY
    Sommerer, C.
    Arns, W.
    Weithofer, P.
    Lehner, F.
    Banas, B.
    van der Giet, M.
    Habicht, A.
    Renders, L.
    Rath, T.
    Bartels, M.
    Pratschke, J.
    Hessel, K.
    Bernhardt, P.
    Witzke, O.
    TRANSPLANT INTERNATIONAL, 2018, 31 : 18 - 19
  • [7] Everolimus with Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplant Recipients: Efficacy and Safety Outcomes from the TRANSFORM Study.
    Chadban, S.
    Mulgaonkar, S.
    Pascual, J.
    Tedesco, H.
    Berger, S.
    Qazi, Y.
    Legendre, C.
    Basic-Jukic, N.
    Bernhardt, P.
    Vincenti, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 475 - 475
  • [8] EVEROLIMUS WITH REDUCED CALCINEURIN INHIBITOR EXPOSURE IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS: INFECTION AND WOUND HEALING OUTCOMES FROM THE TRANSFORM STUDY
    Witzke, O.
    Arns, W.
    Weithofer, P.
    Lehner, F.
    Banas, B.
    van der Giet, M.
    Habicht, A.
    Renders, L.
    Rath, T.
    Bartels, M.
    Pratschke, J.
    Hessel, K.
    Bernhardt, P.
    Sommerer, C.
    TRANSPLANT INTERNATIONAL, 2018, 31 : 18 - 18
  • [9] THE TRANSFORM STUDY: LOWER VIRAL INFECTIONS WITH EVEROLIMUS AND REDUCED CALCINEURIN INHIBITOR VERSUS MYCOPHENOLATE AND STANDARD CALCINEURIN INHIBITOR IN DE NOVO KIDNEY TRANSPLANT PATIENTS AT MONTH 12
    Buchler, M.
    Sommerer, C.
    Mulgaonkar, S.
    Garcia, V.
    Massari, P.
    Kuypers, D.
    Citterio, F.
    Vincenti, F.
    Luo, W. L.
    Bernhardt, P.
    Cruzado, J.
    TRANSPLANT INTERNATIONAL, 2018, 31 : 14 - 14
  • [10] THE TRANSFORM STUDY: LOWER VIRAL INFECTIONS WITH EVEROLIMUS AND REDUCED CALCINEURIN INHIBITOR VERSUS MYCOPHENOLATE AND STANDARD CALCINEURIN INHIBITOR IN DE NOVO KIDNEY TRANSPLANT PATIENTS AT MONTH 12
    Cruzado, Josep
    Mulgaonkar, Shamkant
    Garcia, Valter
    Massari, Pablo
    Kuypers, Dirk
    Buchler, Mathias
    Citterio, Franco
    Vincenti, Flavio
    Luo, Wen-Lin
    Bernhardt, Peter
    Sommerer, Claudia
    TRANSPLANT INTERNATIONAL, 2017, 30 : 159 - 160
12345